Investigating CYP2C9*3 Polymorphisms in Patients with Neuropsychological Disorders through Pharmacogenomics Testing
Braa Elwaleed Mohamed Ahmed, Muhsin Konuk, Tayfun Gözler, Hana Nadir Arbab, Abeer Azhary Sayed Abdoon
This study examines CYP2C9*3 polymorphisms in patients with neuropsychological disorders using pharmacogenomics testing and finds a higher frequency of *1/*1 genotype compared to *1/*3.
medRxiv · Jan 5, 2026 · PreprintGenetic & Genomic Medicine